Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today provided a business
update and reported financial results for the fourth quarter and
year ended December 31, 2021.
“The response to Bylvay from healthcare providers, patients and
payors has been positive. As a result, we are pleased to have
generated a significant number of patient starts that resulted in
sales at the higher end of our 2021 guidance,” said Ron Cooper,
President and Chief Executive Officer of Albireo. “For 2022, we
look forward to increased Bylvay sales with launches in additional
countries, completing enrollment in the two ongoing Phase 3 studies
in Alagille syndrome and biliary atresia, and initiating clinical
studies for both our novel/innovative pipeline compounds for adult
liver and viral diseases.”
2021 and Upcoming Highlights
Bylvay (odevixibat)
Bylvay Launch Metrics |
Full Year 2021 |
Q4 |
Q3 |
Net Sales |
$7.0M ($5.3M U.S., $1.7M Intl) |
$5.9M($4.5M U.S., $1.4M Intl) |
$1.1M ($0.8M U.S., $0.3M Intl) |
Prescriptions (NRx) |
93 |
65 |
28 |
Patients on Bylvay (Approved &
reimbursed) |
53 |
39 |
14 |
Potential Rollover Patients |
~90 |
~90 |
100 |
Unique Prescribers Cumulative(U. S.
only) |
51 |
51 |
19 |
- Bylvay was approved by the U.S. Food & Drug
Administration (FDA) on July 20, 2021 and
launched as the first drug for the treatment of
pruritus in patients 3 months of age and older in all types
of progressive familial intrahepatic cholestasis (PFIC).
- In Europe, Bylvay was authorized on
July 16, 2021 for the treatment of all types of PFIC in patients
aged 6 months or older by the European Commission (EC) and UK
Medicines and Healthcare Products Regulatory Agency (MHRA) on
September 8, 2021. Bylvay is currently available in Germany and is
expected to become available for sale in additional European
countries following country price listings and reimbursement
approvals.
- On February 22, 2022, National
Institute for Health and Care Excellence (NICE) issued guidance
that recommended Bylvay for the treatment of all types of PFIC in
people aged six months and older. With this final recommendation
under the Highly Specialised Technologies (HST) pathway, Bylvay
will be funded for use within 90 days in the National Health
Service in England, Wales and Northern Ireland.
- Pricing and reimbursement for
Bylvay is proceeding according to plan with discussions ongoing in
13 additional countries, of which 10 are in active assessment or
negotiation with payers. In addition to the NICE HST
classification, in France Bylvay has received an SMR “Important”
and ASMR III from the HAS Transparency Committee.
- Bylvay will be available globally
through our exclusive distribution and supply agreements with
Medison Pharma, Ltd. in Israel, GEN İlaç in Turkey, Genpharm
Services in Saudi Arabia and other Gulf countries, Jadeite
Medicines Inc. in Japan and Swixx BioPharma AG in Central and
Eastern Europe.
- The Phase 3 ASSERT study in Alagille syndrome (ALGS) is
enrolling as planned and remains on track to report topline data by
the end of 2022.
- The Phase 3 BOLD study, which is the
first and only Phase 3 study of an IBAT inhibitor in biliary
atresia, has passed the 50% enrollment milestone in 2021 and
remains on track for topline data in 2024. Biliary atresia is the
most common pediatric cholestatic liver disease with no approved
drug treatment.
- The PICTURE study was published in
Orphanet Journal of Rare Disease. A multinational, retrospective,
cross-sectional study, PICTURE evaluated and quantified the impact
that PFIC has on caregivers and found a significant
caregiver-reported burden on health-related quality of life
(HRQoL), impairment of daily activities, reduced sleep, impact on
work productivity, career building challenges and relationship
strain. The study illustrates for the first time that PFIC levies a
substantial burden that extends beyond the individuals with the
disease to those caring for them.
Pipeline: Next Generation Bile Acid
Modulators
- Reported positive topline results
from the Phase 1 clinical trial of A3907, the first and only oral
systemic apical sodium-dependent bile acid transporter (ASBT)
inhibitor in clinical development. The study achieved the
pharmacokinetic, safety and tolerability objectives. The Company
will advance A3907 and plans to initiate a Phase 2 study in adult
liver disease by the end of 2022.
- A2342 is the first oral
sodium-taurocholate co-transporting peptide (NTCP) inhibitor
developed for hepatitis B and D. The Company reported positive in
vitro and in vivo preclinical data on the impact of A2342 on
hepatitis B virus (HBV) infection and demonstrated NTCP target
engagement. Plans are to advance A2342 into Phase 1 first-in-human
studies by the end of 2022.
Corporate
- In October 2021, the Company
entered into an exclusive licensing agreement with Jadeite
Medicines, Inc. for the development and commercialization of Bylvay
in Japan for PFIC, ALGS and biliary atresia. Under the terms of the
agreement, Jadeite Medicines, a biopharmaceutical platform company
focused on developing innovative pharmaceutical products, will be
responsible for clinical development, regulatory approval and
commercialization of Bylvay in Japan, where there is significant
market opportunity. In addition to an upfront payment of $15
million, Albireo is entitled to receive up to $120 million in
milestone payments and double-digit royalties.
- In Q4, the Company announced the
appointment of Constantine Chinoporos as Chief Business Officer and
a member of the Albireo Enterprise Leadership Team, bringing 30
years of experience in business development, new product planning
operations, corporate development, global licensing and
divestitures. Mr. Chinoporos is responsible for creating a forward
integration strategy to accelerate Albireo’s growth and maximize
the value of our opportunities.
- The Company will be presenting at
the upcoming Cowen 42nd Annual Health Care
Conference being held March 7-9, 2022.
Fourth Quarter 2021 Financial Results
- Product revenue, net was $5.9 million for the fourth quarter of
2021 due to Bylvay patient sales and initial inventory stocking at
specialty pharmacies. Bylvay was approved during the third quarter
of 2021, therefore there was no product revenue for the fourth
quarter of 2020.
- Royalty revenue was $11.6 million for the fourth quarter of
2021, compared with $2.7 million for the fourth quarter of 2020, an
increase of $8.9 million. The increase relates to higher estimated
royalty revenue and an achievement of a $8.6 million milestone to
be received from EA Pharma for elobixibat for the treatment of
chronic constipation, which is passed on to HealthCare Royalty
Partners.
- License revenue was $15 million for the fourth quarter of 2021
due to cash received related to the upfront fee from the recently
announced Japan licensing agreement. There was no license revenue
for the fourth quarter of 2020.
- Cost of product revenue was $0.9 million for the fourth quarter
of 2021. Following approval of Bylvay, certain manufacturing and
quality headcount costs are now included in cost of product
revenue. There were no material costs, as materials related to
current product sold was expensed prior to approval. Bylvay was
approved during the third quarter of 2021, therefore there was no
cost of product revenue for the fourth quarter of 2020.
- R&D expenses were $20.6 million for the fourth quarter of
2021 compared with $20.1 million for the fourth quarter of 2020, an
increase of $0.5 million. The increase in R&D expenses for the
fourth quarter of 2021 was principally due to expenses related to
the A3907 study offset by lower expenses for Bylvay studies and
personnel costs.
- Selling, general and administrative expenses were $19.7 million
for the fourth quarter of 2021 compared with $14.2 million for the
fourth quarter of 2020, an increase of $5.6 million. The increase
is attributable to personnel and related expenses as we continue to
increase our headcount, and commercialization activities related to
Bylvay.
- Net loss for the fourth quarter of 2021 was $11.0 million, or
$(0.57) per share, compared to $24.8 million, or $(1.30) per share
for the fourth quarter of 2020.
Financial Results for the Year Ended December 31,
2021
- Product revenue, net was $7.0 million for the year ended
December 31, 2021 due to Bylvay patient sales and initial inventory
stocking at specialty pharmacies. Bylvay was approved during the
third quarter of 2021, therefore there was no product revenue for
the year ended December 31, 2020.
- Royalty revenue was $18.6 million for the year ended December
31, 2021, compared with $8.3 million for the year ended December
31, 2020, an increase of $10.3 million. The increase relates to
higher estimated royalty revenue and an achievement of a $8.6
million milestone to be received from EA Pharma for elobixibat for
the treatment of chronic constipation, which is passed on to
HealthCare Royalty Partners.
- License revenue was $15.0 million for the year ended December
31, 2021 due to cash received related to the upfront fee from the
recently announced Japan licensing agreement. There was no license
revenue for the year ended December 31, 2020.
- Cost of product revenue was $1.4 million for the year ended
December 31, 2021. Following the approval of Bylvay, certain
manufacturing and quality headcount costs are now included in cost
of product revenue. There were no material costs, as materials
related to current product sold was expensed prior to approval.
Bylvay was approved during the third quarter of 2021, therefore
there was no cost of product revenue for the year ended December
31, 2020.
- R&D expenses were $82.5 million for the year ended December
31, 2021 compared with $76.8 million for the year ended December
31, 2020, an increase of $5.7 million. The increase in R&D
expenses for the 2021 period was principally due to expenses
related to the Bylvay Phase 3 studies and A3907, partially offset
by decreases in expenses for preclinical studies, and in the
previous year the completion of the PEDFIC1 study, and the
completion of the elobixibat Phase 2 study in NASH.
- Selling, general and administrative expenses were $69.6 million
for the year ended December 31, 2021 compared with $42.4 million
for the year ended December 31, 2020, an increase of $27.1 million.
The increase is attributable to personnel and related expenses as
we continue to increase our headcount, and commercialization
activities related to Bylvay.
- Net loss for the year ended
December 31, 2021 was $34.0 million, or $(1.77) per share, compared
to $107.6 million, or $(6.73) per share for the year ended December
31, 2020.
- The Company had cash
and cash equivalents of at least $248.1 million as of December 31,
2021 versus $262.6 million as of September 30, 2021. The Company
expects to have sufficient cash into 2024 based on current revenue
and expense projections. Bylvay Q1 2022 sales are expected to be
between $5-6 million.
Conference Call
Albireo will host a conference call and webcast today, March 1st
at 10:00 a.m. ET. To access the live conference call by phone, dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13727211. A live audio webcast will be
accessible from the Investors page at ir.albireopharma.com/. To
ensure a timely connection to the webcast, it is recommended that
participants register at least 15 minutes prior to the scheduled
start time. An archived version of the webcast will be available
for replay on the Events & Presentations section of the
Investors page of Albireo’s website for 3 months following the
event.
About Bylvay (odevixibat)
Bylvay is the first drug approved in the U.S. for the treatment
of pruritus in patients 3 months of age and older in all types of
progressive familial intrahepatic cholestasis (PFIC). Limitation of
Use: BYLVAY may not be effective in PFIC type 2 patients with
ABCB11 variants resulting in non-functional or complete absence of
bile salt export pump protein (BSEP-3). The European Commission
(EC) and UK Medicines and Healthcare Products Regulatory Agency
(MHRA) have also granted marketing authorization of Bylvay for the
treatment of PFIC in patients aged 6 months or older. Bylvay is
available in Germany and the UK and will be available for sale in
other European countries following pricing and reimbursement
approval. A potent, once-daily, non-systemic ileal bile acid
transport inhibitor, Bylvay acts locally in the small intestine.
Bylvay can be taken as a capsule for patients that are able to
swallow capsules, or opened and sprinkled onto food, which is a
factor of key importance for adherence in a pediatric patient
population. The most common adverse reactions for Bylvay are
diarrhea, liver test abnormalities, vomiting, abdominal pain, and
fat-soluble vitamin deficiency. The medicine can only be obtained
with a prescription. For more information about using Bylvay, see
the package leaflet or contact your doctor or pharmacist. For full
prescribing information, visit www.bylvay.com.
In the U.S. and Europe, Bylvay has orphan exclusivity for its
approved PFIC indications, and orphan designations for the
treatment of Alagille syndrome, biliary atresia and primary biliary
cholangitis. Bylvay is being evaluated in the ongoing PEDFIC 2
open-label trial in patients with PFIC, in the BOLD Phase 3 study
for patients with biliary atresia and the ASSERT Phase 3 study for
Alagille syndrome.
Important Safety Information
- The most common adverse reactions for Bylvay are diarrhea,
liver test abnormalities, vomiting, abdominal pain, and fat-soluble
vitamin deficiency.
- Liver Test Abnormalities: Patients should obtain baseline liver
tests and monitor during treatment. Dose reduction or treatment
interruption may be required if abnormalities occur. For persistent
or recurrent liver test abnormalities, consider treatment
discontinuation.
- Diarrhea: Treat dehydration. Treatment interruption or
discontinuation may be required for persistent diarrhea.
- Fat-Soluble Vitamin (FSV) Deficiency: Patient should obtain
baseline vitamin levels and monitor during treatment. Supplement if
deficiency is observed. If FSV deficiency persists or worsens
despite FSV supplementation, discontinue treatment.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat rare pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and it is also being developed to treat other
rare pediatric cholestatic liver diseases with Phase 3 trials in
Alagille syndrome and biliary atresia, as well as an Open-label
Extension (OLE) study for PFIC. In Europe, Bylvay has been approved
for the treatment of PFIC with pricing listing in Germany and
guidance from the National Institute for Health and Care Excellence
(NICE) recommending Bylvay for use in the National Health Service
in the England, Wales and Northern Ireland UK. The Company has also
completed a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
progressing with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. The Boston Business Journal named Albireo one
of the 2019 and 2020 Best Places to Work in Massachusetts. For more
information on Albireo, please visit www.albireopharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements, other than
statements of historical fact, regarding, among other things:
Albireo’s commercialization plans; the plans for, or progress,
scope, cost, initiation, duration, enrollment, results or timing
for availability of results of, development of Bylvay, A3907, A2342
or any other Albireo product candidate or program; the PEDFIC 2
open-label trial in patients with PFIC; the pivotal trial for
Bylvay in biliary atresia (BOLD); the pivotal trial for Bylvay in
Alagille syndrome (ASSERT); the Phase 2 study for A3907 the
IND-enabling or clinical studies for A2342; the target
indication(s) for development or approval; the timing for
initiation or completion of or availability or reporting of results
from any clinical trial, including the long-term open-label
extension study for Bylvay in PFIC, the BOLD and ASSERT trials, the
Phase 2 study for A3907, and the IND-enabling and clinical studies
for A2342; expectations that biliary atresia is the most common
pediatric cholestatic liver disease with no approved drug
treatment; expectations that the Company’s distribution and supply
agreements will drive availability of Bylvay in key markets
globally, and potential revenue that may be generated by such
agreements; potential regulatory approval and plans for potential
commercialization of Bylvay in additional countries; the potential
benefits or competitive position of Bylvay or any other Albireo
product candidate or program or the commercial opportunity in any
target indication; Bylvay’s funding for use in the National Health
Service in England, Wales and Northern Ireland; future price
listings and reimbursement approvals of Bylvay; the length of time
for which Albireo’s cash resources are expected to be sufficient;
or Albireo’s plans, expectations or future operations, financial
position, revenues, costs or expenses. Albireo often uses
words such as “anticipates,” “believes,” “plans,” “expects,”
“projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,” “planned,” “continue,”
“guidance,” or the negative of these terms or other similar
expressions to identify forward-looking statements. Actual results,
performance or experience may differ materially from those
expressed or implied by any forward-looking statement as a result
of various risks, uncertainties and other factors, including, but
not limited to: there are no guarantees that Bylvay will be
commercially successful; we may encounter issues, delays or other
challenges in commercializing Bylvay; whether Bylvay receives
adequate reimbursement from third-party payors; the degree to which
Bylvay receives acceptance from patients and physicians for its
approved indication; challenges associated with execution of our
sales activities, which in each case could limit the potential of
our product; challenges associated with supply and distribution
activities, which in each case could limit our sales and the
availability of our product; results achieved in Bylvay in the
treatment of patients with PFIC may be different than observed in
clinical trials, and may vary among patients; other potential
negative impacts of the COVID-19 pandemic, including on
manufacturing, supply, conduct or initiation of clinical trials, or
other aspects of our business; whether favorable findings from
clinical trials of Bylvay to date, including findings in
indications other than PFIC, will be predictive of results from
other clinical trials of Bylvay; there is no guarantee that Bylvay
will be approved in jurisdictions or for indications beyond the
jurisdictions in which or indications for which Bylvay is currently
approved; there is no guarantee that our other products candidates
will be approved; estimates of the addressable patient population
for target indications may prove to be incorrect; the outcome and
interpretation by regulatory authorities of the ongoing third-party
study pooling and analyzing of long-term PFIC patient data; the
timing for initiation or completion of, or for availability of data
from, clinical trials of Bylvay, including BOLD and ASSERT and the
Phase 2 clinical trial of A3907, and the outcomes of such trials;
Albireo’s ability to obtain coverage, pricing or reimbursement for
approved products in the United States or Europe; delays or other
challenges in the recruitment of patients for, or the conduct of,
the Company’s clinical trials; and the Company’s critical
accounting policies. These and other risks and uncertainties that
Albireo faces are described in greater detail under the heading
“Risk Factors” in Albireo’s most recent Annual Report on Form 10-K
or in subsequent filings that it makes with the Securities and
Exchange Commission. As a result of risks and uncertainties that
Albireo faces, the results or events indicated by any
forward-looking statement may not occur. Albireo cautions you not
to place undue reliance on any forward-looking statement. In
addition, any forward-looking statement in this press release
represents Albireo’s views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. Albireo disclaims any obligation to update
any forward-looking statement except as required by applicable
law.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma, Inc.
Consolidated Balance
Sheets(in thousands, except share and per share
data)
|
|
December 31, |
|
December 31, |
|
|
2021 |
|
|
2020 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
248,107 |
|
|
$ |
251,272 |
|
Accounts receivable, net |
|
|
3,272 |
|
|
|
— |
|
Inventory |
|
|
194 |
|
|
|
— |
|
Prepaid expenses |
|
|
5,261 |
|
|
|
7,564 |
|
Other current assets |
|
|
12,096 |
|
|
|
3,029 |
|
Total current assets |
|
|
268,930 |
|
|
|
261,865 |
|
Property and equipment, net |
|
|
668 |
|
|
|
478 |
|
Goodwill |
|
|
17,260 |
|
|
|
17,260 |
|
Other assets |
|
|
15,193 |
|
|
|
6,004 |
|
Total assets |
|
$ |
302,051 |
|
|
$ |
285,607 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
6,516 |
|
|
$ |
5,283 |
|
Accrued expenses |
|
|
35,951 |
|
|
|
19,051 |
|
Other current liabilities |
|
|
2,880 |
|
|
|
948 |
|
Total current liabilities |
|
|
45,347 |
|
|
|
25,282 |
|
Liability related to sale of future royalties |
|
|
60,132 |
|
|
|
65,894 |
|
Note payable, net of discount |
|
|
10,004 |
|
|
|
9,621 |
|
Other long-term liabilities |
|
|
10,960 |
|
|
|
3,579 |
|
Total liabilities |
|
|
126,443 |
|
|
|
104,376 |
|
Stockholders’ Equity: |
|
|
|
|
|
|
Preferred stock, $0.01 par value per share — 50,000,000 shares
authorized at December 31, 2021 and
December 31, 2020; 0 and 0 shares issued and outstanding
at December 31, 2021 and December 31, 2020,
respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value per share — 60,000,000 and 30,000,000
shares authorized at December 31, 2021 and
December 31, 2020, respectively; 19,304,312 and
19,296,552 shares issued and outstanding at
December 31, 2021, respectively, and 19,107,040 shares
issued and outstanding at December 31, 2020 |
|
|
193 |
|
|
|
191 |
|
Additional paid-in capital |
|
|
475,390 |
|
|
|
456,472 |
|
Accumulated other comprehensive income (loss) |
|
|
1,105 |
|
|
|
(8,612 |
) |
Accumulated deficit |
|
|
(300,850 |
) |
|
|
(266,820 |
) |
Treasury stock at cost, 7,760 shares and 0 shares at December 31
2021 and December 31, 2020, respectively |
|
|
(230 |
) |
|
|
— |
|
Total stockholders’ equity |
|
|
175,608 |
|
|
|
181,231 |
|
Total liabilities and stockholders’ equity |
|
$ |
302,051 |
|
|
$ |
285,607 |
|
Albireo Pharma, Inc.
Consolidated Statements of
Operations(in thousands, except share and per
share data)
|
|
Three Months Ended December 31, |
|
|
Year Ended December 31, |
|
|
2021 |
|
|
2020 |
|
|
|
2021 |
|
|
2020 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue, net |
|
$ |
5,933 |
|
|
$ |
— |
|
|
|
$ |
6,993 |
|
|
$ |
— |
|
Royalty revenue |
|
|
11,588 |
|
|
|
2,716 |
|
|
|
|
18,586 |
|
|
|
8,308 |
|
License revenue |
|
|
15,000 |
|
|
|
— |
|
|
|
|
15,000 |
|
|
|
— |
|
Total revenue |
|
|
32,521 |
|
|
|
2,716 |
|
|
|
|
40,579 |
|
|
|
8,308 |
|
Cost of product revenue |
|
|
925 |
|
|
|
— |
|
|
|
|
1,356 |
|
|
|
— |
|
Gross profit |
|
|
31,596 |
|
|
|
2,716 |
|
|
|
|
39,223 |
|
|
|
8,308 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
20,602 |
|
|
|
20,050 |
|
|
|
|
82,522 |
|
|
|
76,777 |
|
Selling, general and administrative |
|
|
19,744 |
|
|
|
14,158 |
|
|
|
|
69,569 |
|
|
|
42,448 |
|
Other operating expense (income), net |
|
|
2,744 |
|
|
|
(10,090 |
) |
|
|
|
10,617 |
|
|
|
(14,646 |
) |
Total operating expenses |
|
|
43,090 |
|
|
|
24,118 |
|
|
|
|
162,708 |
|
|
|
104,579 |
|
Operating loss |
|
|
(11,494 |
) |
|
|
(21,402 |
) |
|
|
|
(123,485 |
) |
|
|
(96,271 |
) |
Other income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain from sale of priority review voucher, net of transaction
costs |
|
|
— |
|
|
|
— |
|
|
|
|
103,387 |
|
|
|
— |
|
Interest expense, net |
|
|
(3,257 |
) |
|
|
(3,397 |
) |
|
|
|
(13,932 |
) |
|
|
(11,362 |
) |
Net loss before income taxes |
|
|
(14,751 |
) |
|
|
(24,799 |
) |
|
|
|
(34,030 |
) |
|
|
(107,633 |
) |
Benefit for income taxes |
|
|
3,789 |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
Net loss |
|
$ |
(10,962 |
) |
|
$ |
(24,799 |
) |
|
|
$ |
(34,030 |
) |
|
$ |
(107,633 |
) |
Net loss per common share - basic and diluted |
|
$ |
(0.57 |
) |
|
$ |
(1.30 |
) |
|
|
$ |
(1.77 |
) |
|
$ |
(6.73 |
) |
Weighted-average common shares used to compute basic and diluted
net loss per common share |
|
|
19,290,017 |
|
|
|
19,082,963 |
|
|
|
|
19,220,846 |
|
|
|
15,983,058 |
|
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024